FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP)

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Lalwani Nikhil					2. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ANIP]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Laiwani Niknii						[MM]								X Director				10% Ov	vner	
(Last)	(Fi	rst) (M	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 02/29/2024								X	Office below	er (give title v)		Other (s	specify	
C/O ANI PHARMACEUTICALS, INC.						02/29/2024									PRESIDENT & CEO					
210 MAIN STREET WEST						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)															X Form filed by One Reporting Person					
BAUDETTE MN 56623														Form filed by More than One Reportin Person						
(City)	Rul	Rule 10b5-1(c) Transaction Indication																		
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											nded to									
		Table	I - No	n-Deriva	tive S	Secui	rities	Acq	juired,	, Dis	posed of	, or E	Benefic	cially	own (ed				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Executif any	eemed ution Date, / th/Day/Year)					s Acquired (A) of (D) (Instr. 3, 4		and Securit Benefit Owned		ties cially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) (D)	or Pric	е	Report Transa (Instr. 3	ported ansaction(s) str. 3 and 4)			(Instr. 4)		
Common Stock 02/2				02/29/2	2024				F ⁽¹⁾		10,014	D	\$6′	\$67.67		473,946		D		
		Tal	ble II -								osed of, c				Owne	d				
1. Title of Derivative Security (Instr. 3)	of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)		ite	Amount		Dei Sed (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Becurities Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	Code V (A) (D)		Date Expira Exercisable Date		Expiration Date	Title	Amount or Number of Shares								

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 23,882 shares of restricted stock, the grant of which was previously reported.

Remarks:

/s/ Nikhil Lalwani, by attorney-in-fact Meredith W. Cook

03/01/2024

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.